RARA CRAFT DATABASE for FDA Medical Devices
PMAP190032S001

FDA DEVICE FACTS

FoundationOne Liquid CDx (F1 Liquid CDx)

Foundation Medicine, Inc.

Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。

DECISION DATEJuly 15, 2021PRODUCT CODEPQP

Indications for use

FoundationOne® Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology to detect and report substitutions, insertions and deletions (indels) in 311 genes, including rearrangements in four (4) genes, and copy number alterations in three (3) genes. FoundationOne® Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of cancer patients collected in FoundationOne® Liquid CDx cfDNA blood collection tubes included in the FoundationOne® Liquid CDx Blood Sample Collection Kit. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling.

Table 1: Companion diagnostic indications Tumor T ype Biomarker(s) Detected Therap y Non-small cell lung cancer (NSCLC) ALK Rearrangements ALECENSA ® (alectinib) EGFR Exon 19 deletions and EGFR Exon 21 L858R alteration IRESSA® (gefitinib) TAGRISSO® (osimertinib) TARCEVA® (erlotinib) MET single nucleotide variants (SNVs) and indels that lead to MET exon 14 skipping TABRECTA® (capmatinib)

Prostate cancer BRCA1, BRCA2, and ATM alterations LYNPARZA ® (olaparib) BRCA1, BRCA2 alterations RUBRACA ® (rucaparib) Ovarian Cancer BRCA1, BRCA2 alterations RUBRACA ® (rucaparib) Breast Cancer PIK3CA mutations C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y PIQRAY ® (alpelisib)

Additionally, FoundationOne® Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

A negative result from a plasma specimen does not mean that the patient’s tumor is negative for genomic findings. Patients who are negative for the mutations listed in Table 1 should be reflexed to routine biopsy and their tumor mutation status confirmed using an FDA-approved tumor tissue test, if feasible.

Genomic findings other than those listed in Table 1 of the intended use statement are not prescriptive or conclusive for labeled use of any specific therapeutic product.

FoundationOne ® Liquid CDx is a single-site assay performed at Foundation Medicine, Inc. in Cambridge, MA.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: September 2, 2026